Serum CEACAM1 Elevation Correlates with Melanoma Progression and Failure to Respond to Adoptive Cell Transfer Immunotherapy

Figure 5

The changes in serum CEACAM1 in patients responding to treatment correlate with those in LDH. sCEACAM1 and LDH levels were tested at the same time points before and following immunotherapy for 26 AJCC stage IV patients. The baseline, pretreatment levels of sCEACAM1 (or LDH) were then subtracted from posttreatment levels and plotted as black (sCEACAM1) or white (LDH) circles for each of the patients.